TW200608991A - Chemokine combinations to mobilize progenitor/stem cells - Google Patents

Chemokine combinations to mobilize progenitor/stem cells

Info

Publication number
TW200608991A
TW200608991A TW094127548A TW94127548A TW200608991A TW 200608991 A TW200608991 A TW 200608991A TW 094127548 A TW094127548 A TW 094127548A TW 94127548 A TW94127548 A TW 94127548A TW 200608991 A TW200608991 A TW 200608991A
Authority
TW
Taiwan
Prior art keywords
stem cells
chemokine
mobilize progenitor
combinations
progenitor
Prior art date
Application number
TW094127548A
Other languages
English (en)
Inventor
Gary J Bridger
Louis M Pelus
Original Assignee
Anormed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anormed Inc filed Critical Anormed Inc
Publication of TW200608991A publication Critical patent/TW200608991A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
TW094127548A 2004-08-13 2005-08-12 Chemokine combinations to mobilize progenitor/stem cells TW200608991A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60136704P 2004-08-13 2004-08-13

Publications (1)

Publication Number Publication Date
TW200608991A true TW200608991A (en) 2006-03-16

Family

ID=35908186

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094127548A TW200608991A (en) 2004-08-13 2005-08-12 Chemokine combinations to mobilize progenitor/stem cells

Country Status (9)

Country Link
US (1) US20060035829A1 (zh)
EP (1) EP1796716A4 (zh)
JP (1) JP2008509928A (zh)
CN (1) CN101094684A (zh)
AU (1) AU2005272653A1 (zh)
BR (1) BRPI0514343A (zh)
CA (1) CA2577046A1 (zh)
TW (1) TW200608991A (zh)
WO (1) WO2006020891A2 (zh)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8435939B2 (en) * 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
BRPI0615180A2 (pt) * 2005-08-19 2011-05-03 Genzyme Corp método para intensificar a quimioterapia
MX2008010895A (es) * 2006-02-24 2008-09-03 Genzyme Corp Metodos para aumentar el flujo sanguineo y/o promover la regeneracion de tejidos.
JP5257068B2 (ja) 2006-05-16 2013-08-07 小野薬品工業株式会社 保護されていてもよい酸性基を含有する化合物およびその用途
US20090325992A1 (en) 2006-07-31 2009-12-31 Ono Pharmaceutical Co., Ltd. Compound having cyclic group bound thereto through spiro binding and use thereof
CN101495115A (zh) * 2006-08-02 2009-07-29 健赞股份有限公司 组合治疗
EP3011961B1 (en) * 2006-12-21 2020-11-11 Biokine Therapeutics LTD. 4f-benzoyl-tn14003 for the mobilisation of hematopoietic progenitor cells in view of transplantation
MX2011013459A (es) * 2009-06-14 2012-05-08 Biokine Therapeutics Ltd Terapia de peptido para incrementar los niveles de plaquetas.
MX365242B (es) 2011-05-16 2019-05-28 Genzyme Corp El uso del antagonista cxcr4: 1,1´-[1,4-fenileno-bis-(metileno)-bi s-1, 4, 8, 11-tetraazaciclotetradecano (plerixaflor) para el tratamiento del síndrome de whim.
CN103159690B (zh) * 2011-12-14 2015-03-25 朱靖华 对称大环胺化合物的结晶形式
EP2841084B1 (en) 2012-04-24 2018-05-30 Biokine Therapeutics Ltd. Cxcr4 antagonist peptide for use in the treatment of large cell lung cancer
AU2013270674B2 (en) 2012-06-07 2017-12-07 Children's Hospital Los Angeles Methods for treating neutropenia using retinoid agonists
CN105431521A (zh) * 2013-02-28 2016-03-23 哈佛学院校长同事会 用于动员干细胞的方法和组合物
CN106413701A (zh) 2014-02-18 2017-02-15 洛杉矶儿童医院 用于治疗中性粒细胞减少症的组合物和方法
CA3026154A1 (en) * 2015-06-03 2016-12-08 The University Of Queensland Mobilizing agents and uses therefor
EP3322431A2 (en) 2015-07-16 2018-05-23 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
AU2017222495B2 (en) 2016-02-23 2019-08-08 Biolinerx Ltd. Methods of treating acute myeloid leukemia
WO2017147610A1 (en) * 2016-02-26 2017-08-31 President And Fellows Of Harvard College Highly engraftable hematopoietic stem cells
WO2018085574A2 (en) * 2016-11-02 2018-05-11 Washington University Compositions comprising an integrin inhibitor and agents which interact with a chemokine and methods of use thereof
BR112019021282A2 (pt) 2017-04-12 2020-05-19 Magenta Therapeutics Inc antagonistas de receptor aril hidrocarboneto e usos dos mesmos
AU2018358241A1 (en) 2017-10-31 2020-05-07 Edigene Biotechnology, Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells
EP3703715A1 (en) 2017-10-31 2020-09-09 Magenta Therapeutics, Inc. Compositions and methods for hematopoietic stem and progenitor cell transplant therapy
US10058573B1 (en) * 2017-12-06 2018-08-28 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem cells
WO2019113375A2 (en) * 2017-12-06 2019-06-13 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
CN111902411A (zh) 2018-01-03 2020-11-06 美真达治疗公司 用于扩增造血干细胞和祖细胞以及治疗遗传性代谢紊乱的组合物和方法
EP4051298A1 (en) 2019-11-01 2022-09-07 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progentor cells
EP4143302A1 (en) 2020-04-27 2023-03-08 Magenta Therapeutics, Inc. Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo
EP4308694A1 (en) 2021-03-16 2024-01-24 Magenta Therapeutics, Inc. Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680174A (en) * 1984-05-24 1987-07-14 Damon Biotech, Inc. Induction of immune response by immunization with encapsulated antigen-producing cells
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5021409A (en) * 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
US6001826A (en) * 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
GB9126677D0 (en) * 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
JP4006021B2 (ja) * 1993-06-08 2007-11-14 スミスクライン・ビーチャム・コーポレイション ケモカインの生物学的活性の強化法
DE4320478B4 (de) * 1993-06-21 2007-11-15 Robert Bosch Gmbh Fahrstabilitätsregler
EP0741580A4 (en) * 1993-12-14 2001-07-11 Univ Johns Hopkins Med CONTROLLED RELEASE OF PHARMACEUTICALLY ACTIVE SUBSTANCES FOR IMMUNOTHERAPY
GB9400411D0 (en) * 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
US6506770B1 (en) * 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
GB9511357D0 (en) * 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
US6713052B1 (en) * 1995-10-24 2004-03-30 Human Genome Sciences, Inc. Method of mobilizing stem cells with chemokine β-8
EP1016726A1 (en) * 1998-12-30 2000-07-05 Introgene B.V. Gene therapy to promote angiogenesis
US6365583B1 (en) * 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
US6750348B1 (en) * 1999-03-24 2004-06-15 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
CN100335478C (zh) * 1999-12-17 2007-09-05 阿诺麦德股份有限公司 结合趋化因子受体的杂环化合物
WO2002022599A2 (en) * 2000-09-15 2002-03-21 Anormed Inc. Chemokine receptor binding heterocyclic compounds
US6734191B2 (en) * 2000-09-15 2004-05-11 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
AU9156901A (en) * 2000-09-15 2002-03-26 Anormed Inc Chemokine receptor binding heterocyclic compounds
MXPA03002772A (es) * 2000-09-29 2003-07-28 Anormed Inc Procedimiento para la preparacion de poliaminas ciclicas que contienen nitrogeno en el anillo n-1 protegidos y productos de los mismos.
CA2443685A1 (en) * 2001-04-03 2002-10-17 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
MXPA04000982A (es) * 2001-07-31 2004-04-20 Anormed Inc Metodos para movilizar celulas progenitoras/madre.
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
EP1451297A4 (en) * 2001-12-07 2006-06-28 Toolgen Inc PHENOTYPIC SCANNING OF CHIMERIC PROTEINS
WO2004091518A2 (en) * 2003-04-11 2004-10-28 Anormed Inc. Cxcr4 chemokine receptor binding compounds
US7550484B2 (en) * 2003-04-22 2009-06-23 Genzyme Corporation Chemokine receptor binding heterocyclic compounds with enhanced efficacy
EP1708703A4 (en) * 2003-12-11 2008-04-09 Anormed Inc CHEMOKIN RECEPTOR BINDING COMPOUNDS

Also Published As

Publication number Publication date
EP1796716A4 (en) 2010-09-08
WO2006020891A2 (en) 2006-02-23
BRPI0514343A (pt) 2008-06-10
CN101094684A (zh) 2007-12-26
WO2006020891A3 (en) 2006-07-13
EP1796716A2 (en) 2007-06-20
US20060035829A1 (en) 2006-02-16
AU2005272653A1 (en) 2006-02-23
JP2008509928A (ja) 2008-04-03
CA2577046A1 (en) 2006-02-23

Similar Documents

Publication Publication Date Title
TW200608991A (en) Chemokine combinations to mobilize progenitor/stem cells
MXPA04000982A (es) Metodos para movilizar celulas progenitoras/madre.
SG165322A1 (en) Engineered anti-il-23 antibodies
WO2007095594A3 (en) Methods and compositions for enhancing engraftment of hematopoietic stem cells
CL2013000261A1 (es) Compuestos derivados de heterociclos nitrogenados, con actividad ampk; composicion farmaceutica; metodos in vitro; y su uso en enfermedades cardiovasculares, diabetes tipo ii, distrofia muscular, trastornos neurolgicos, enfermedades inflamatorias, entre otras.
EP2056381A4 (en) CELL, ELECTRODE AND COLLECTOR USED THEREIN
WO2005099775A3 (en) Labeled anwexin for predicting the response to a therapeutic regimen
MX2009009079A (es) Anticuerpos anti-il-23p19 de ingenieria.
MX2009009080A (es) Anticuerpos anti-interleucina-23p19 manipulados por ingenieria genetica.
WO2008006895A3 (en) Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta t cell activators
DK1846974T3 (da) Membran-elektrode samlinger til brændstofceller, deres fremstilling og anvendelse og brændstofceller indeholdende disse
MX2007008136A (es) Metodo para invertir la resistencia multiple en celulas animales.
MX2009009283A (es) Anticuerpos anti-interleuquina -23r de ingenieria.
DK1916729T3 (da) Nikkeloxidpulvermateriale til fast elektrolytbrændselsbatteri, fremgangsmåde til fremstilling deraf, råmaterialesammensætning til anvendelse i samme, og brændselselektrodemateriale med anvendelse af nikkeloxidpulver
ECSP077416A (es) Mimeticuerpos que se unen al receptor de melanocortina, composiciones, metodos y usos
IL179884A0 (en) Fuel cells, micro-fuel cells and methods for the production thereof
BRPI0814931A2 (pt) Composto com atividade contra hcv, sua composição e seu uso
DK1743029T3 (da) Cellefremstilling
EP1951290A4 (en) AGENT FOR USE IN THE CASE OF INTOLERANCE TO FRUCTOSE
WO2005079868A3 (en) Crf receptor antagonists, their preparations, their pharmaceutical composition and their uses
YaLing et al. Professional Work and Social Responsibility of Editor of Stomatology Journals in Facing Strong Earthquake
程炜 Do You Have Enough Sleep?
松本逸郎 Brain mast cells act as an immune gate to the hypothalamic-pituitary-adrenal axis in dogs
丁大琴 New Planet Could Be Earthlike, Scientists Say
Zarva HIGHER EDUCATION IN THE USA AND UKRAINE: THE SYSTEMS'DIFFERENCES